India-EU FTA: Will Turkish goods enter India under the newly signed trade deal?

The EU and India concluded an FTA that will make 96.8% of tariff lines preferential, covering 99.5% of India’s exports by volume and 90.7% by value to the EU duty-free, but Turkish goods cannot enter India duty-free under the deal even if routed via EU ports because Turkiye is not a signatory and does not meet India–EU rules of origin. Under the EU–Turkiye customs union Ankara must mirror EU external tariff cuts for third countries, which forces it to extend tariff reductions to Indian goods without gaining reciprocal market access. Bilateral trade has already weakened: India’s exports to Turkiye fell 14.1% to $5.71bn in 2024–25 (from $6.65bn) and imports from Turkiye dropped about 20.8% to ~$3bn; Turkiye accounted for ~1.3% of India’s $437bn exports in 2023–24.

Analysis

Market structure: The India–EU FTA materially raises competitive pressure on EU importers (and Indian exporters) by making ~96.8% of tariff lines duty-free, likely boosting Indian export volumes to the EU by 5–15% annually in first 12–24 months versus baseline. Winners: Indian export-oriented sectors (pharma, auto parts, textiles) and EU re-exporters; losers: Turkish exporters seeking indirect access to India and any Turkish exporters competing with Indian product lines. FX/bond cross-effects: expect modest INR appreciation (100–300bp over 6–12 months) and mild spread compression for INR sovereign debt; potential widening in TRY spreads if geopolitical frictions persist.

Risk assessment: Tail risks include EU Parliament rejection, Indian political backlash, or Turkish legal challenge to customs-union interpretation — each could reverse flows within weeks and trigger ±10–20% moves in small-cap exporters or Turkey-focused assets. Immediate (days): low market reaction until legal text and ratification timetable; short-term (weeks–months): trade re-routing and customs rule clarifications; long-term (years): structural shift in supply chains away from Turkey for India-bound exports. Hidden dependencies: strict rules-of-origin and customs enforcement; transshipment fraud risk could invite enforcement and fines.

Trade implications: Primary trades: go long India-exposure ETFs (INDA or EPI) via 3–6 month call spreads sized 2–3% of portfolio; hedge with short positions in Turkey ETF (TUR) 1–2%. Use USD/INR 6–12 month forward longs (1–2% notional) to capture expected INR strength. Options: buy 3–6 month INDA 10–15% OTM call spreads; buy TUR 3-month puts as asymmetric hedge. Rotate from Turkey-exposed industrials/steel to Indian pharma/auto suppliers over 3–12 months.

Contrarian angles: The market underestimates enforcement complexity — aggressive customs audits or India’s political sensitivity to Turkey could slow flows, creating a 6–12 month window where Indian exporters underdeliver despite tariff cuts. Conversely, rapid circumvention via non-EU transshipment hubs (UAE/Singapore) is plausible, which would blunt Turkish losses and create short-lived arbitrage in freighters and port stocks. Historical parallel: NAFTA rule-of-origin disputes show multi-year friction before stable trade patterns emerge; plan for 10–25% volatility in niche exporters and logistics names during ratification.

Key Decisions for Investors

• Establish a 2–3% portfolio long via INDA (iShares MSCI India ETF) using a 3–6 month call spread (buy 6%–12% OTM calls, sell 20%–30% OTM calls) to capture expected 5–15% export upside post-ratification; target +12–25% in 6–12 months, stop loss -8%.
• Allocate a 1–2% short via TUR (iShares MSCI Turkey ETF) or buy 3-month puts on TUR sized to 1% notional as a hedge against TRY widening and lost export access; take profits on a 15% move down or cut at -10% adverse move.
• Buy USD/INR forwards or call spread (6–12 month tenor) sized 1–2% of FX exposure to capture anticipated INR appreciation of 100–300bp; unwind within 12 months or on INR strengthening >300bp vs current spot.
• Reallocate 3–5% of EM equity exposure from Turkey-exposed cyclicals (steel, textiles) into Indian pharma/auto parts suppliers (via EPI/INDA or names like INFY-weighted exporters) over 30–90 days post-official signing; monitor EU ratification calendar and exit/trim if ratification delayed >90 days or if customs-origin clarifications disadvantage Indian goods.